title: [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas.
abstract: OBJECTIVE
  To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas.
  
  
  METHODS
  FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas. FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung. Ki-67, cyclin D1 and p53 staining scores were examined by immunohistochemistry.
  
  
  RESULTS
  The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography. The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12. The latter had significantly higher CR value than the former (P < 0.001). Patients with CR > or = 0.55 could be predicted to be at advanced tumor stages, with a sensitivity of 0.83 and a specificity of 0.82. The CR and staining scores of Ki-67 were significantly correlated with each other (P < 0.0001), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features (P < 0.05-0.0001).
  
  
  CONCLUSIONS
  In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67. For c-stage IA lung adenocarcinomas showing CR > or = 0.55, mediastinoscopy or neoadjuvant chemotherapy is indicated.
authors.affiliation: Department of Thoracic Surgery, Saiseikai Central Hospital, Tokyo, Japan.
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Watanabe
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nomori
authors.forename: Takashi
authors.initials: T
authors.lastname: Ohtsuka
authors.forename: Tsuguo
authors.initials: T
authors.lastname: Naruke
authors.forename: Akinori
authors.initials: A
authors.lastname: Ebihara
authors.forename: Hideki
authors.initials: H
authors.lastname: Orikasa
authors.forename: Kazuto
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Kimiichi
authors.initials: K
authors.lastname: Uno
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Goya
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D049109:Cell Proliferation; D019938:Cyclin D1 / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18; D016147:Genes, Tumor Suppressor; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D019394:Ki-67 Antigen; D019275:Radiopharmaceuticals; D016159:Tumor Suppressor Protein p53; D019788:Fluorodeoxyglucose F18; D019938:Cyclin D1